Paul Grossman, MD
Interventional Cardiology · Ann Arbor, MINPI 1720164460
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $528,672 of the $630,445 with a category attached, or 83.9%. Medtronic accounts for 97.0% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2022 at $156,639 and has fallen 72.5% since, to $43,150 in 2025. Among interventional cardiology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,166 payments — averaging $540.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$612K
- Shockwave Medical, Inc$16K
- Edwards Lifesciences$837
- Abbott$772
- Boston Scientific$523
- Siemens Medical Solutions USA, Inc.$149
- plus $522 from 7 others
Across 80 payments — averaging $6351.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cardiovascular Systems Inc.$327K
- Medtronic$101K
- W. L. Gore & Associates, Inc.$41K
- Abbott$40K
What the payments were for
- Consulting fees$2,7500%
- Speaking & faculty fees$528,67284%
- Travel & lodging$66,62211%
- Food & beverage$32,0815%
- Education$380%
- Other$2820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 1,119 | $611,671 |
| Shockwave Medical, Inc | 13 | $15,972 |
| Edwards Lifesciences | 13 | $837 |
| Abbott | 4 | $772 |
| Boston Scientific | 6 | $523 |
| Siemens Medical Solutions USA, Inc. | 1 | $149 |
| Abiomed | 1 | $143 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $119 |
| Surmodics, Inc. | 1 | $117 |
| Teleflex LLC | 2 | $65 |
| Johnson & Johnson | 1 | $38 |
| Biotronik Inc. | 1 | $34 |
| Procyrion, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$327,798
- CoreValve Evolut$239,997
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$15,771
- Resolute$11,313
- SYMPLICITY G3$2,392
- SAPIEN 3 Ultra RESILIA$504
- PORTICO$463
- Supera peripheral stent system$158
- GENERAL - THERAPIES$154
- ESPRIT$150
- Artis icono floor$149
- Impella$143
- Pounce Thrombectomy$117
- Pounce Venous Thrombectomy System$117
- Pounce Thrombectomy System$117
- Pounce LP Thrombectomy$117
- 3F$106
- GENERAL - STRUCTURAL HEART$103
How this compares
$630,445 in reported general payments places this provider in the 95th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 39 | $45,002 |
| XareltoRivaroxaban | 14 | $19,331 |
| ClopidogrelClopidogrel Bisulfate | 104 | $2,131 |
| Atorvastatin Calcium | 94 | $1,642 |
| Rosuvastatin Calcium | 34 | $667 |
| Metoprolol Succinate | 34 | $435 |
| Losartan Potassium | 19 | $363 |
| Prasugrel Hcl | 11 | $341 |
| Lisinopril | 31 | $258 |
| Carvedilol | 17 | $253 |
| Warfarin Sodium | 11 | $248 |
| Spironolactone | 15 | $222 |
| Metoprolol Tartrate | 35 | $189 |
| Omeprazole | 22 | $165 |
| Amlodipine Besylate | 28 | $155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $38 | $19,33114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Ann Arbor
- Daniel MeneesAnn Arbor$136K
- Amir KakiDetroit$1.8M
- Tamam MohamadDetroit$960K
- Jason RicciPetoskey$594K
- Tim FischellKalamazoo$468K
- Mir BasirDetroit$442K
- Amr AbbasBerkley$416K
- Safwan KassasSaginaw$340K
- Vishal GuptaKalamazoo$293K
- Khaldoon AlaswadDetroit$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.